AI Article Synopsis
- A study was conducted to evaluate the effectiveness of the polymer-free biolimus coated stent (BioFreedom) in a diverse patient population undergoing coronary interventions, specifically focusing on those with high bleeding risk (HBR) versus non-HBR patients.
- The study included 1497 patients and measured the incidence of target lesion failure (TLF) as its primary outcome, finding a higher occurrence of TLF in HBR patients (9.2%) compared to non-HBR patients (5.8%).
- Results indicated that HBR patients faced greater risks of cardiac death and target vessel myocardial infarction, while also experiencing higher bleeding rates, confirming the need for careful patient management in this high-risk group.
Article Abstract
Background: The polymer-free biolimus coated stent (BioFreedom) was shown to be superior to bare metal stents in the LEADERS FREE randomized trial in high bleeding risk (HBR) patients treated with 1-month dual antiplatelet therapy (DAPT). However, there is limited outcome data with this device in an all-comers' population.
Methods: We conducted a prospective single-arm study of patients undergoing percutaneous coronary intervention with the polymer-free biolimus coated stent in 25 centers in France with wide inclusion criteria including multivessel disease, complex lesions, and acute coronary syndromes. The primary endpoint was the incidence of target lesion failure (TLF), a composite of cardiac death or target-vessel myocardial infarction (MI) or clinically indicated target lesion revascularization (ci-TLR) at 1-year. The patient population was classified according to the presence (or not) of HBR criteria according to the recent ARC-HBR definition.
Results: Between April 2019 and April 2020, 1497 patients were enrolled. TLF occurred in 101 (6.9%) patients, including cardiac death in 35 (2.4%), target vessel MI in 20 (1.4%) and ci-TLR in 65 (4.5%) of them. There were 491 HBR patients (32.8%) and 1006 non-HBR patients. The median duration of DAPT was 74 days in the HBR group versus 348 days in the non-HBR group (p < 0.0001). TLF occurred in 44 (9.2%) of the HBR group and in 57 (5.8%) of the non-HBR group (relative risk 1.62 [95% confidence interval: 1.10-2.41], p = 0015). Compared to the non-HBR group, HBR patients had higher rates of cardiac death (4.4% vs. 1.4%, p = 0.0005) and target vessel MI (2.9% vs. 0.6%, p = 0.0003), but similar rates of ci-TLR. BARC 3-5 bleeding occurred in 6.2% of the HBR group versus 1.4% of the non-HBR group (p < 0.0001).
Conclusion: In this multicenter all-comers study, HBR patients treated with a polymer-free biolimus coated stent had, compared to non-HBR patients, an increased risk of cardiac death and MI, and despite a shorter duration of DAPT, continued to have higher rates of BARC 3-5 bleeding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.30481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polymer free biolimus coated stents to treat acute ST-elevation myocardial infarction in Asian patients.
Catheter Cardiovasc Interv
December 2024
Queen Elizabeth Hospital, Hong Kong, China.
Background: Patients undergoing primary percutaneous coronary intervention (PPCI) for ST-segment-elevation myocardial infarction (STEMI) have a high thrombotic burden and often have a high bleeding risk (HBR). Asian patients have different patterns of thrombotic and bleeding risk from other populations which may be particularly relevant in the setting of PPCI for STEMI.
Objectives: To assess the safety and efficacy of the polymer free biolimus coated coronary stent (PF-BCS, BioFreedom, Biosensors International) in Asian STEMI patients.
Efficacy and safety of polymer-free biolimus-eluting stents versus durable polymer novolimus-eluting stents in a real-world clinical practice (FREEDOM-DES trial).
Hellenic J Cardiol
September 2024
Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
Impact of 12-Month Angioscopic Thrombi and Yellow Plaque After Drug-Eluting Stent Implantation.
Circ J
October 2024
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
Article Synopsis
- The study analyzed the effects of coronary angioscopy (CAS) findings after the implantation of two types of stents: a polymer-free biolimus A9-coated stent (PF-BCS) and a durable polymer everolimus-eluting stent (DP-EES) in 99 patients, with evaluations done at 1 and 12 months post-implantation.
- Results showed a decrease in thrombi and yellow plaque from 1 month to 12 months, with no new thrombi but some new yellow plaque observed in patients with DP-EES.
- Key factors affecting thrombi development included management of diabetes, stent area, and stent coverage, highlighting that polymer
Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years.
Open Heart
June 2024
Institut Cardiovasculaire Paris Sud, Massy, France.
Background: For high bleeding-risk patients (HBR) undergoing percutaneous coronary intervention (PCI), the LEADERS FREE (LF) and LEADERS FREE II (LF II) trials established the safety and efficacy of a stainless steel polymer-free biolimus-coated stent (SS-BCS) with 30 days of dual antiplatelet treatment (DAPT). The LEADERS FREE III (LF III) trial investigated clinical outcomes after PCI with the next-generation cobalt-chromium thin-strut polymer-free biolimus-coated stent (CoCr-BCS) in HBR patients.
Aims: To report the final 3-year results of the LF III trial and compare them to LF II.
Safety and efficacy of the latest generation biodegradable polymer-coated ultrathin sirolimus-eluting stent in the treatment of coronary artery disease in a European all-comer population with or without high bleeding risk: The Cruz HBR Registry.
Minerva Cardiol Angiol
August 2024
Facharztpraxis Baldeney, Essen, Germany.
Article Synopsis
- The Supraflex Cruz sirolimus-eluting stent (SES) shows promising early healing properties and is effective for patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
- A study involving 1203 patients, with 38.7% classified as HBR, measured safety and efficacy through a composite endpoint, finding higher cardiovascular events in HBR patients compared to non-HBR ones (8.1% vs. 4.4%).
- Results confirmed the Supraflex Cruz's non-inferiority in both HBR and non-HBR groups when compared to established stent trials, indicating it is a safe option for this patient population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!